A low-cost, high-quality new drug discovery process using patient-derived induced pluripotent stem cells

- Preclinical animal models are not reliable for human clinical trials.
- Post-marketing failure and black box warnings of approved market drugs are shown.
- Key gates for low-cost and high-quality drug discovery process are presented.
- Creation of a global iPS cell bank based on genetic polymorphisms of drug metabolism is discussed.
- Diseases display in a dish using iPS cells without need for animal models.